Seeking Alpha

Alnylam PT boosted to $94 at Needham

  • Analyst Alan Carr reiterates his Buy rating and boosts the price target to $94 from $65 following last night's Q4 results.
  • "Management reiterated plans to bring at least 6-7 candidates into clinical development by YE15, including two into Phase 3 by YE14," he notes. "Key milestones this year include data from the ALN-TTRsc Phase 2, ALN-AT3 Phase 1, and ALN-TTR02 Phase 2 OLE trials, all in 4Q14."
  • "The Jan 2014 Sanofi collaboration provides a large cash infusion, allowing a much larger R&D effort that may accelerate time to commercialization of multiple programs across multiple territories."
  • The $94 price target is based on 25x 2020 EPS estimates, discounted by 25% annually.
  • ALNY unchanged premarket
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: